Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 135-140

  Müller, Walter E ^a   Koch, Sabrina ^a   Scheuer, Klaus ^a   Rostock, Angelika ^b   Bartsch, Reni ^b  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b Arzneimittelwerk Dresden   (Germany)

Author keywords

aging; cognitive functions; fluidity; membrane; piracetam

Indexed keywords

ALCOHOL; OXIRACETAM; PIRACETAM; PRAMIRACETAM;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN; BRAIN REGION; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MEMBRANE FLUIDITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

AGED; AGING; ANIMALS; BRAIN; FEMALE; HUMANS; MALE; MEMBRANE FLUIDITY; MICE; NEUROPROTECTIVE AGENTS; PIRACETAM; RATS; RATS, WISTAR;

EID: 0342437559     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00463-7     Document Type: Article

References (33)

1. Kruse H and Konler H, Memory enhancing effects of piracetam in aged rats. Abstr Fed Proc 37: 888, 1978.
2. Valzelli L, Bernasconi S and Sala A, Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatr 15: 150-156, 1980.
3. Giurgea CE, The nootropic concept and its prospective implications. Drug Dev Res 2: 441-446, 1982.
4. Gouliaev AH and Senning A, Piracetam and other structurally related nootropics. Brain Res Rev 19: 180-222, 1994.
5. Sun AY and Sun GY, Neurochemical aspects of the membrane hypothesis of aging. Interdiscip Top Gerontol 15: 34-53, 1979.
6. Bonetti AC, Battistella A, Calderini G, Teolato S, Crews FT, Gaiti A, Algeri S and Toffano G, Biochemical alterations in the mechanisms of synaptic transmission in aging brain. In: Aging of the Brain (Eds. Samuel D et al.), pp. 171-181. Raven Press, New York, 1983.
7. Shinitzky M, Heron DS and Samuel D, Restoration of membrane fluidity and serotonin receptors in the aged mouse brain. In: Aging of the Brain (Eds. Samuel D et al.), pp. 329-336. Raven Press, New York, 1983.
8. Joseph JA, Yamagami K and Roth GS, Loss of muscarinic responsiveness in senescence may be the result of decreased membrane fluidity. Soc Neurosci Abstr 17: 53, 1991.
9. Viani P, Cervato G, Fiorilli A and Cestaro B, Age-related differences in synaptosomal peroxidative damage and membrane properties. J Neurochem 56: 253-258, 1991.
10. Tacconi MT, Lligoña L, Salmona M, Pitskas N and Algeri S, Aging and food restriction: Effects on lipids of cerebral cortex. Neurobiol Aging 12: 55-59, 1991.
11. Scheuer K, Stoll S, Paschke U, Weigel R and Müller WE, N-Methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging. Pharmacol Biochem Behav 50: 65-70, 1995.
12. Schroeder F, Gorka C and Wood WG, Neuronal membrane asymmetry and aging. In: Central Nervous System Disorders of Aging: Clinical Intervention and Research (Eds. Strong R et al.), pp. 211-222. Raven Press, New York, 1988.
13. Ghosh C, Dick RM and Ali SF, Iron/ascorbate-induced lipid peroxidation changes membrane fluidity and muscarinic cholinergic receptor binding in rat frontal cortex. Neurochem Int 23: 479-484, 1993.
14. 32P into the phospholipids of neurons and glial cells isolated from rabbit cerebral cortex. Pharmacopsychiatria 12: 251-256, 1979.
15. Trovarelli G, Gaiti A, DeMedio G, Brunetti M and Porcellati G, Biochemical studies on the nootropic drug oxiracetam in brain. Clin Neuropharmacol 7(Suppl 1). Raven Press, New York, 1984.
16. Fassoulaki A, Kostopanagiotou G, Kaniaris P and Varonos D, Changes in phospholipid monolayers produced by general anaesthetics are partially inhibited by piracetam. Br J Anaesth 60: 330P, 1988.
17. Spignoli G, Pedata F, Giovannelli L, Banfi S, Moroni F and Pepeu G, Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition. Clin Neuropharmacol 9(Suppl 3): S39-S47. Raven Press, New York, 1986.
18. 14C-Piracetam im Affengehirn. Arzneim Forsch (Drug Res) 28(1): 29-35, 1978.
19. 14C bei Ratte und Hund. Arzneim Forsch (Drug Res) 25(4): 589-596, 1975.
20. Peuvot J, Schanck A, Deleers M and Brasseur R, Piracetam-induced changes to membrane physical properties. Biochem Pharmacol 50: 1129-1134, 1995.
21. Shinitzky M and Barenholz Y, Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim Biophys Acta 515: 367-370, 1978.
22. Haugland RP, Handbook of Fluorescence Probes and Research Chemicals, 5th ed. Molecular Probes, Eugene, Oregon, 1992.
23. Zs-Nagy I, An attempt to answer the questions of theoretical gerontology on the basis of the membrane hypothesis of aging. Adv Biosci 64: 393-413, 1987.
24. Pugsley TA, Shih YH, Coughenour L and Stewart SF, Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Drug Dev Res 3: 407-420, 1983.
25. 1-adrenergic signal transduction of the aged rat cerebral cortex. J Neurochem 55: 70-75, 1990.
26. Cimino M, Vantini G, Algeri S, Curatola G, Pezzoli C and Stramentinoli G, Age-related modification of dopaminergic and β-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 34: 2029-2039, 1984.
27. Muccioli G, Scordamaglia A, Bertacco S and DiCarlo R. Effects of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 227: 293-299, 1992.
28. Pilch H and Müller WE, Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology 94: 74-78, 1988.
29. Stoll L, Schubert T and Müller WE, Age-related deficits of central muscarinic cholinergic receptor function in the mouse. Partial restoration by chronic piracetam treatment. Neurobiol Aging 13: 39-44, 1992.
30. 3H-N-methylscopolamine binding in cerebral cortex of young and old rats. Life Sci 50: 971-977, 1992.
31. Müller WE, Hartmann H, Koch S, Scheuer K and Stoll S, Neurotransmission in aging - Therapeutic aspects. In: Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction (Eds. Racagni G, Brunello N and Langer SZ). Int Acad Biomed Drug Res 7: 166-173. Karger, Basel, 1994.
32. Cohen SA and Müller WE, Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology 47: 217-222, 1993.
33. Heron DS, Shinitzky M, Hershkowitz M and Samuel D, Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Natl Acad Sci USA 77: 7463-7467, 1980.